Remote Patient Monitoring Platform Comparison 2026: A Buyer’s Guide for Clinics

Choosing a remote patient monitoring platform in 2026 is no longer a binary decision between “monitoring” and “not monitoring.” Clinics now face a crowded vendor landscape spanning consumer-grade wearables, billing-optimized chronic care platforms, condition-specific devices, and research-grade biosensor systems built for clinical-trial rigor. The stakes are high: the wrong platform choice can mean poor data fidelity, reimbursement friction, and patient dropout — while the right one can transform chronic disease management and open new revenue streams through CPT-coded remote monitoring programs.

remote patient monitoring platform selection should start with clinical workflow fit, validated device data, billing documentation, patient adherence, and EHR integration—not with a feature checklist alone.

remote patient monitoring platform verification checklist

• Confirm which physiologic data are collected, whether devices are FDA-cleared when required, and how missing data are handled.
• Map CPT documentation needs, escalation protocols, and staff time before signing a vendor contract.
• Review security, consent, patient onboarding, EHR integration, and export access for quality reporting.

Related Sensor Bio reading: remote patient monitoring, RTM vs RPM, and remote therapeutic monitoring.

Authoritative references include the CMS digital health coverage resources, CMS care management payment resources, and FDA Digital Health Center of Excellence.

This guide is written for clinic administrators, medical directors, and telehealth directors who need to make a defensible, auditable vendor decision. We cover what to evaluate, how the major platform categories differ, and the specific questions you should put to every vendor before signing a contract.

What to Evaluate Before Choosing an RPM Platform

Before comparing vendors side by side, a clinic needs clarity on its own requirements. The most common mistake in RPM procurement is selecting a platform based on a demo rather than on a structured needs assessment. Six dimensions should anchor that assessment.

Device type: consumer vs. clinical-grade. Consumer devices like smartwatches are optimized for comfort and compliance. Clinical-grade devices are validated against reference standards, offer raw signal access, and are typically subject to FDA clearance or CE marking. For reimbursement purposes, CMS guidance does not currently mandate FDA-cleared devices for RPM billing, but clinical judgment and liability exposure argue for validated hardware in higher-acuity populations.

Data ownership. Who owns the physiological data generated by your patients? Some platforms retain rights to de-identified data for secondary use. For hospital systems and academic medical centers running prospective studies, this is non-negotiable — data must remain within your governance boundary. Review the data processing agreement, not just the BAA.

EHR integration. Bidirectional HL7 FHIR integration with Epic or Cerner is table stakes for high-volume programs. Confirm whether the vendor has a certified SMART on FHIR app, a direct integration, or a manual CSV export workflow. Manual export is workable for pilots; it does not scale.

Billing support. RPM reimbursement under CPT codes 99457 and 99458 requires documented time logs, device setup records, and qualifying physiological data transmission. Some platforms automate this documentation; others leave it to the clinic. Understand exactly what the platform generates versus what your staff must create manually.

Patient onboarding complexity. Platforms with consumer-grade hardware and app-driven onboarding typically achieve 60–75% patient activation rates. Clinical platforms with proprietary hardware require more hands-on setup but often deliver higher data completeness in enrolled patients.

Condition coverage. A platform designed for diabetes management may have excellent CGM integration but limited support for cardiac or pulmonary monitoring. Confirm that the device portfolio matches your patient panel.

RPM Platform Categories

The RPM market has fragmented into five recognizable categories, each with a distinct value proposition and a different clinical use case profile.

General chronic disease platforms — companies like CareSimple and Prevounce — offer broad condition coverage, pre-built billing workflows, and device procurement services. They are designed for primary care and internal medicine practices looking to launch a reimbursable RPM program with minimal technical complexity. Data fidelity is typically limited to summary metrics.

Condition-specific platforms focus on a single physiology domain. CGM-centric platforms (Dexcom Clarity, Abbott LibreView) provide deep glucose analytics but limited support for other biometric streams. Cardiac platforms (iRhythm Zio, Biotricity) deliver clinical-grade ECG monitoring but are not designed for multi-signal chronic disease programs.

Research-grade and clinical trial platforms occupy a separate category entirely. These platforms — including Sensor Bio — are built around raw signal fidelity, configurable data pipelines, and the audit-trail requirements of IRB-regulated studies. They are the appropriate choice for academic medical centers, health systems running prospective outcome studies, and specialty clinics where physiological signal quality directly informs clinical decisions.

What distinguishes research-grade from clinical-grade in this context? Three things: access to raw physiological waveforms (not just derived metrics), IRB-ready data export formats with timestamped audit trails, and an SDK or API that allows institutional data teams to build custom analytics. General RPM platforms do not offer these capabilities.

Key Evaluation Criteria

The following seven criteria provide the structured framework for a defensible vendor comparison.

Device Accuracy and Validation

Ask every vendor for their device validation study citations. FDA clearance (510(k) or De Novo) indicates the device has met a predicate-based accuracy standard, but the specific indication and validation population matter. A device cleared for adult ambulatory SpO2 monitoring may not be validated in patients with peripheral vascular disease. For research use, ISO 81060-2 compliance for NIBP and IEEE 11073 compliance for waveform interoperability are relevant benchmarks.

Data Granularity

This is the sharpest differentiator between platform categories. Consumer wellness platforms and general RPM platforms typically deliver summary metrics: daily step counts, nightly average SpO2, resting heart rate. Clinical and research platforms provide time-series physiological data — beat-to-beat RR intervals, raw photoplethysmography waveforms, continuous temperature streams. For chronic disease programs where trend detection and anomaly identification are the clinical goal, summary metrics are often insufficient.

Biometric Signal Coverage

Evaluate each platform’s sensor modality coverage: heart rate variability, ECG, PPG, SpO2, skin temperature, and accelerometry are the core signals for most chronic disease applications. Platforms vary significantly in which signals are captured continuously versus spot-check, and whether raw waveform data is accessible or only processed metrics.

EHR Integration

Confirm HL7 FHIR R4 compliance and, specifically, which FHIR resource types are supported (Observation, Patient, Device, CarePlan). Vendor claims of “Epic integration” range from a certified SMART on FHIR app to a manual HL7 v2 file drop. The former is operationally viable; the latter creates FTE burden. Ask for the integration architecture document, not just a feature checklist.

Billing and CPT Documentation

For programs billing CPT 99457 (first 20 minutes monthly) and 99458 (additional 20-minute increments), the platform must generate time-stamped interaction logs and device data transmission records. Ask specifically: does the platform generate a CMS-compliant monthly summary report, or does your team assemble that documentation manually?

Patient Compliance Tooling

Alert threshold configuration, escalation pathways, and patient-facing engagement tools (app notifications, check-in prompts) directly affect program compliance rates. Higher compliance correlates with better reimbursement capture and, more importantly, better clinical outcomes. Evaluate the platform’s default alert logic and whether thresholds can be customized per patient or per condition protocol.

Data Ownership and HIPAA Compliance

Confirm the vendor will execute a Business Associate Agreement. Review whether patient data is used for any secondary purpose, including platform improvement or AI model training. For health systems operating under state privacy laws more stringent than HIPAA (California CMIA, for example), confirm the vendor’s compliance posture under applicable state law.

Platform Type Comparison: Five Categories

Rather than ranking specific vendors — who update features and pricing continuously — this section compares the five platform archetypes across the criteria above.

Consumer wellness platforms (Garmin, Apple Watch with third-party RPM apps). These platforms excel at patient compliance: patients already own and wear the devices, onboarding friction is minimal, and app ecosystems are mature. Their clinical limitations are significant: data fidelity is limited by consumer sensor sampling rates, raw waveform access is generally unavailable, and FDA clearance is either absent or limited in scope. For low-acuity chronic disease monitoring where trend direction matters more than signal precision, consumer platforms may be cost-effective. For any program where clinical decisions depend on physiological signal quality, they are not appropriate.

CGM-centric platforms (Dexcom, Abbott LibreView). These are best-in-class for glucose monitoring, with validated accuracy, strong EHR integration (particularly with Epic’s Dexcom partnership), and robust patient-facing apps. Their limitation is scope: they are glucose platforms, not multi-signal RPM platforms. A diabetes program that also needs to monitor blood pressure, weight, or cardiac rhythm will need a second vendor or a companion platform.

General RPM platforms (CareSimple, Prevounce). These platforms are optimized for billing efficiency and operational simplicity in primary care. They offer a device procurement catalog, pre-built CPT documentation workflows, and care coordination tooling. Data granularity is limited to summary metrics, and raw signal access is not available. For practices whose primary goal is launching a reimbursable RPM program with low operational overhead, these platforms are a reasonable starting point. They are not appropriate for clinical research, high-acuity monitoring, or programs where physiological signal quality drives clinical decisions.

Cardiac-specific platforms (Biotricity, iRhythm Zio). These platforms deliver clinical-grade ECG monitoring for arrhythmia detection and cardiac event documentation. They are appropriate for cardiology practices with a specific need for extended ECG monitoring. Their limitation is that they are single-modality platforms: ECG-focused design means limited or no support for other biometric streams, and they are not built for multi-condition chronic disease programs.

Research-grade biosensor platforms (Sensor Bio). Sensor Bio’s platform is built around raw physiological signal capture, configurable data pipelines, and the documentation requirements of IRB-regulated clinical research. The hardware captures continuous multi-signal waveforms — ECG, PPG, SpO2, temperature, accelerometry — with SDK access for institutional data teams. Data ownership remains with the institution. This platform category is appropriate for academic medical centers, health systems running prospective studies, specialty clinics where signal fidelity is clinically determinative, and any program where the monitoring data may be used in peer-reviewed research or regulatory submissions.

Questions to Ask Every RPM Vendor

Use this list as the foundation for your RFP or vendor discovery calls. Any vendor unable to answer these questions with specificity is not ready for clinical deployment at scale.

• What device validation studies support your accuracy claims, and in which patient populations were they conducted?
• Do you provide access to raw physiological waveform data, or only processed summary metrics?
• What is your HL7 FHIR version support, and which FHIR resource types are included in your integration?
• Do you have a certified SMART on FHIR application available in the Epic App Orchard or Cerner App Gallery?
• What CPT documentation does the platform generate automatically, and what must our staff produce manually?
• Who owns the patient data, and is it used for any secondary purpose including platform improvement or AI model training?
• What is your BAA structure, and have you completed HIPAA compliance assessments under applicable state privacy laws?
• What is your historical patient activation rate across client deployments, and how do you define activation?
• What is your uptime SLA, and what is your incident response process for data transmission failures?
• Can you provide three client references from organizations with a similar patient panel and program scope to ours?

Billing and Reimbursement Considerations

Remote patient monitoring reimbursement under Medicare is governed by two CPT code families, each with distinct documentation and time requirements.

CPT 99457 covers the first 20 minutes of clinical staff time per calendar month spent reviewing RPM data and engaging with the patient. CPT 99458 covers each additional 20-minute increment. Both require that the device collects physiological data at a minimum of 16 days per 30-day period and that a qualifying physician order is on file. Time must be clinical in nature — data review, care plan adjustment, patient communication — and must be documented with sufficient specificity to survive an audit.

For programs incorporating therapeutic rather than purely physiological monitoring, the RTM CPT codes 98975–98981 cover a separate service category. Understanding the boundary between RPM and remote therapeutic monitoring is essential for programs that monitor adherence, musculoskeletal function, or respiratory therapy. The two billing pathways cannot be billed concurrently for the same service period under most payer policies.

Payer coverage beyond Medicare varies significantly. Commercial payer policies for RPM range from full coverage with documentation requirements similar to Medicare to no coverage at all. Medicaid coverage is state-by-state. Before deploying an RPM program, confirm reimbursement coverage for the specific CPT codes with each payer in your patient panel. For a detailed comparison of RTM vs RPM billing structures, see our dedicated guide.

Frequently Asked Questions

What is the difference between RPM and RTM?

Remote patient monitoring (RPM) involves the collection of physiological data — blood pressure, heart rate, glucose, SpO2, weight — using medical devices. Remote therapeutic monitoring (RTM) involves the collection of non-physiological data related to therapeutic adherence and response, such as medication adherence, musculoskeletal performance, or respiratory therapy compliance. The two are governed by different CPT code families and have different device and documentation requirements. See our RTM vs RPM comparison for a detailed breakdown.

What CPT codes apply to RPM?

The primary RPM billing codes are CPT 99457 (first 20 minutes of monthly monitoring and management) and CPT 99458 (each additional 20-minute increment). Device setup and patient education at the start of a monitoring program can be billed under CPT 99453 and 99454. Each code has specific documentation, time, and device transmission requirements that must be met per billing period.

Does my clinic need FDA-cleared devices for RPM billing?

CMS does not explicitly require FDA clearance for devices used in RPM programs billed under 99457/99458. CMS guidance specifies that devices must be “medical devices” as defined under Section 201(h) of the Federal Food, Drug, and Cosmetic Act. In practice, most legal and compliance teams interpret this as requiring FDA clearance or registration. Consumer wellness devices without any FDA designation carry legal risk for clinical billing programs and are generally not recommended for reimbursable RPM.

How do I choose between consumer-grade and clinical-grade RPM?

The decision should be driven by the clinical question your program is designed to answer. If the goal is broad engagement, trend monitoring in a low-acuity population, and maximum enrollment at minimum cost, consumer-grade devices may be appropriate. If the goal is physiologically precise monitoring, research-quality data for outcomes reporting, or monitoring in higher-acuity populations where signal accuracy is clinically determinative, clinical-grade or research-grade hardware is the appropriate choice. Consider liability exposure and payer audit risk when making this determination.

What wearable signals matter most for chronic disease monitoring?

Signal selection should match the condition being monitored. For cardiovascular conditions, ECG rhythm strips and continuous heart rate variability capture are most informative. For respiratory conditions, SpO2 and respiratory rate matter most. For metabolic conditions, CGM glucose data is primary. Across chronic conditions generally, accelerometry provides mobility and activity context that modifies interpretation of all other signals. For multi-condition programs, a platform that captures ECG, PPG, SpO2, temperature, and accelerometry continuously provides the most clinically versatile dataset.